Hepatic and extrahepatic malignancies in primary sclerosing cholangitis

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells

“…1 Chronic inflammatory disorders of the biliary tract predispose individuals to the development of this cancer. [2][3][4] These clinical observations implicate inflammatory mediators in the development and progression of this neoplasm. Current concepts suggest that cancer development requires activation of a proliferative program coupled with inhibition of cell death programs.…”

Desarrollo de neoplasia en pacientes con enfermedad inflamatoria intestinal

“…El colangiocarcinoma se ha asociado a múltiples factores de riesgo, destacando la CEP y la EII 4,25 . Un estudio sueco que incluyó 604 pacientes, 79% con EII, demostró una frecuencia de colangiocarcinoma de 13% tras una mediana de seguimiento de 5,7 años 26 . En nuestro estudio, una paciente con CU desarrolló este tipo de neoplasia presentando como factor de riesgo la presencia de CEP.…”

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

“…Patients with PSC have a 100-fold higher risk of biliary tumors, when compared to the general population, with a reported prevalence of 5%-15% (238)(239)(240)(241)(242)(243) . The most common type of cancer is CC.…”

“…CC can also be encountered in cystic biliary diseases, including Caroli disease (242) . Aggravation of jaundice as well as clinical and biochemical deterioration are common findings in patients with CC, but they are also usually found in subjects with progressive PSC without cancer (238)(239)(240)(241)(242) . Gallbladder cancer can be found in subjects with PSC, with a lifetime prevalence of 2% (238,241) .…”